DEF: Agilent Technologies Outlines 2026 Annual Meeting Agenda

Agilent Technologies' latest proxy statement details proposals for its 2026 annual meeting, including director elections, executive compensation, auditor ratification, and a significant board declassification initiative.

Summary

• Agilent Technologies will hold its Annual Meeting of Stockholders on March 18, 2026, to vote on four key proposals.
• The Board of Directors recommends the election of four director nominees: Judy Gawlik Brown, Sue H. Rataj, George A. Scangos, Ph.D., and Dow R. Wilson, each for a three-year term.
• Stockholders will vote on a non-binding advisory basis to approve the compensation of named executive officers for fiscal year 2025.
• The Audit and Finance Committee's appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 will be ratified.
• A significant amendment to the Certificate of Incorporation is proposed to declassify the Board of Directors over a three-year period, leading to annual elections for all directors starting in 2029.
• For fiscal year 2025, Agilent reported revenue growth of 6.7% to $6.9 billion and non-GAAP diluted EPS growth of 5.7% to $5.59.
• GAAP diluted EPS grew by 3.2% to $4.57, while GAAP operating margin decreased by 7.0% to 21.3%.
• The company's Total Shareholder Return (TSR) for fiscal year 2025 was 13.2%, compared to the S&P 500 TSR of 21.5%.
• Short-term incentive payouts for executives ranged from 92% to 108%, with overall corporate funding at 86% of target.
• Long-term incentive plan payouts for the FY23-FY25 period were 118% for relative TSR (55th percentile) and 64% for adjusted EPS.
• The Board has committed to achieving net-zero greenhouse gas emissions by 2050 and announced near and long-term reduction targets in 2023.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting solid financial performance in key areas and proactive corporate governance enhancements, particularly the board declassification. However, the slight decline in operating margin and mixed executive compensation payouts for EPS suggest areas for continued focus.

Positives

• Revenue grew by 6.7% to $6.9 billion in fiscal year 2025.
• Non-GAAP diluted EPS increased by 5.7% to $5.59 in fiscal year 2025.
• GAAP diluted EPS increased by 3.2% to $4.57 in fiscal year 2025.
• Long-term incentive payouts for relative Total Shareholder Return (TSR) for the FY23-FY25 period were strong at 118% of target, indicating outperformance against peers.
• The Board's proposal to declassify the Board over a three-year period, leading to annual elections for all directors by 2029, is a positive corporate governance enhancement, responsive to stockholder feedback.
• The company maintains strong corporate governance practices, including 10 of 11 independent directors, annual Board self-assessments, and robust stock ownership guidelines.
• Commitment to net-zero greenhouse gas emissions by 2050 and reporting on climate-related risks (TCFD) and sustainability (SASB, GRI) demonstrates a focus on corporate responsibility.
• Stockholder support for the 2025 Say-on-Pay proposal was 89%, indicating confidence in the executive compensation program.

Negatives

• GAAP operating margin decreased by 7.0% to 21.3% in fiscal year 2025.
• Non-GAAP operating margin decreased by 2.7% to 25.7% in fiscal year 2025.
• Agilent's Total Shareholder Return (TSR) of 13.2% for fiscal year 2025 was below the S&P 500 TSR of 21.5%.
• Long-term incentive payouts for adjusted EPS for the FY23-FY25 period were 64% of target, indicating underperformance against internal EPS goals.
• Overall short-term incentive funding for executives was 86% of target, reflecting financial targets coming in below plan.
• Mr. McMahon forfeited all fiscal year 2025 stock grants and short-term incentive payout due to his resignation.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially, as detailed in the Annual Report on Form 10-K for the fiscal year ended October 31, 2025.
• The company faces cybersecurity threats, requiring continuous investment in people, processes, and tools to strengthen its security posture.
• Compensation policies and practices could potentially create risks that are reasonably likely to have a material adverse effect on the Company, though an annual assessment did not identify significant risks in FY25.
• The company operates in an evolving industry environment, requiring deep engagement with management on strategy, competitive position, and technological developments.
• The macroeconomic environment presents both challenges and opportunities for the life sciences industry.

Future Outlook

The company plans to simplify its Short-Term and Long-Term Incentive Plans for fiscal year 2026 to improve clarity and reinforce accountability. The Short-Term Incentive Plan will be based on 50% Revenue, 25% Operating Margin, and 25% EPS, with strategic and individual performance modifiers. The Long-Term Incentive Plan will eliminate 1-year EPS goals, transitioning to 60% PSUs based on 3-year relative TSR against the S&P 500 Healthcare Index and 40% time-based RSUs. The one-year post-vest holding period will become a guideline for CEO staff to hold 50% of shares until ownership guidelines are met, and the use of stock options will be discontinued.

Management Comments

• "Our executive compensation program incorporates a number of compensation governance best practices and aligns to our commitment to pay for performance."
• "Based on their assessment, the Board and the Audit and Finance Committee believe that the appointment of PricewaterhouseCoopers LLP is in the best interests of the Company and our stockholders."
• "The Board believes it is in the best interests of our stockholders to provide for the elimination of the classified Board structure over a three-year period."
• "Agilent delivered consistent, profitable growth while navigating a dynamic macroeconomic environment that presented both challenges and opportunities for the life sciences industry."
• "Agilent's strong financial results reflect the successful implementation of the Ignite Transformation enterprise operating model, which emphasizes operational excellence, innovation, and customer centricity."
• "We are pleased that our stockholders continue to show support for our compensation programs, as demonstrated by our most recent Say on Pay proposal vote result of 89% and the strong sentiments received on our executive compensation program during individual stockholder outreach meetings that occurred the past year."
• "The Compensation Committee remains committed to ensuring that Agilents executive compensation programs are aligned with our pay-for-performance philosophy and continue to support the companys strategic priorities and long-term shareholder value."

Industry Context

StockSavvy.ai notes that Agilent Technologies' focus on profitable growth amidst a dynamic macroeconomic environment, particularly capitalizing on global regulatory trends like PFAS testing and increased pharmaceutical R&D in China, positions it within key industry drivers. The shift in long-term incentive metrics to focus solely on relative TSR against the S&P 500 Healthcare Index, removing the Materials Index, reflects a strategic narrowing of its competitive lens, aligning more closely with specialized life sciences and diagnostics peers rather than broader industrial materials companies. This could indicate a more refined competitive strategy and a desire to benchmark against a more directly comparable set of companies like Thermo Fisher and Danaher, which are also mentioned as direct competitors for talent.

Comparison to Industry Standards

• Agilent's fiscal year 2025 revenue growth of 6.7% is solid, but its Total Shareholder Return (TSR) of 13.2% lagged the broader S&P 500 TSR of 21.5%, suggesting underperformance relative to the general market.
• The 118% payout for relative TSR in the FY23-FY25 long-term incentive plan, placing Agilent at the 55th percentile of S&P 500 healthcare and materials companies, indicates above-median performance against a broad peer group, which is a positive sign for executive alignment with shareholder value creation.
• The 64% payout for adjusted EPS in the same long-term incentive plan suggests that while TSR was strong, internal EPS targets were more aggressive or challenging to meet, potentially indicating a gap between market perception and operational profitability goals compared to peers like Thermo Fisher or Danaher, which often demonstrate consistent EPS growth.
• The proposed declassification of the Board aligns Agilent with a growing trend among S&P 500 companies towards enhanced corporate governance and increased director accountability, moving away from staggered boards which are often viewed as entrenchment mechanisms.
• The commitment to net-zero greenhouse gas emissions by 2050 and reporting based on TCFD, SASB, and GRI standards places Agilent among leading companies in environmental sustainability reporting, comparable to best practices seen in large-cap industrial and healthcare firms.

Management Changes

Corporate Governance

Related Party Transactions

• Commercial transactions with AstraZeneca, where Pascal Soriot serves as Chief Executive Officer, were reviewed, approved, and ratified by the Nominating/Corporate Governance Committee.
• Commercial transactions with Pfizer, where Mikael Dolsten, M.D., Ph.D., served as President of Worldwide Research, Development and Medical until February 2025, were reviewed, approved, and ratified by the Nominating/Corporate Governance Committee.
• Commercial transactions with the University of Texas Southwestern Medical Center (UTSW), where Daniel K. Podolsky, M.D., serves as President, were reviewed, approved, and ratified by the Nominating/Corporate Governance Committee.

Stakeholder Impact

• Shareholders: Potential for increased accountability and responsiveness from the Board due to declassification. Continued alignment of executive compensation with shareholder interests through performance-based incentives.
• Employees: Changes to incentive compensation programs for fiscal year 2026, including new metrics and equity award types, will impact executive and potentially broader employee motivation and rewards. Workforce Management Program provides severance benefits for employees affected by restructuring.
• Customers: Continued focus on "delivering insights and innovation" and "customer centricity" through the Ignite Transformation operating model.
• Suppliers/Partners: Proactive actions taken to protect the health and safety of partners and suppliers.
• Regulatory Authorities: Compliance with SEC, NYSE, and other regulatory requirements is a key focus, including cybersecurity risk management and corporate responsibility disclosures.

Next Steps

• Stockholders to vote on four proposals at the Annual Meeting on March 18, 2026.
• Election of four directors to a three-year term.
• Advisory vote on named executive officer compensation.
• Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm.
• Vote on the amendment to declassify the Board of Directors over a three-year period.
• Implementation of new Short-Term and Long-Term Incentive Plans for fiscal year 2026, including changes to metrics and equity award types.
• Annual elections for Board members will begin with the annual meeting in 2027, applying to all Board members starting in 2029, if Proposal 4 passes.
• Mr. Elinoff will assume the role of Senior Vice President and Chief Financial Officer effective November 17, 2025.
• Mr. Gonsalves will transition back to Vice President, Corporate Controller and Principal Accounting Officer effective November 17, 2025.

Key Dates

Recommendation

The filing presents a mixed financial picture with solid revenue and non-GAAP EPS growth, but a decline in operating margins and mixed long-term incentive payouts. While the proposed board declassification is a strong positive for corporate governance, the overall financial performance does not indicate a significant catalyst for a 'buy' recommendation. The company appears to be on a steady course with strategic adjustments, warranting a 'hold' as investors await further clarity on the impact of new incentive structures and sustained margin improvement.

Keywords

Agilent Technologies, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Board Declassification, Director Election, Financial Performance, Revenue Growth, EPS Growth, Operating Margin, Total Shareholder Return, Sustainability, Cybersecurity, Risk Management, Shareholder Engagement, PricewaterhouseCoopers, DEF 14A